Horton J, Gelber R D, Engstrom P, Falkson G, Moertel C, Brodovsky H, Douglass H
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):65-8.
In a study of 127 patients with advanced measurable pancreatic cancer, objective response rates of 2% (melphalan), 10% (5-FU and methyl-CCNU), and 7% (5-FU, methyl-CCNU, and streptozocin) were achieved. No responses occurred in the 28 patients treated with VP-16-213 who had already received prior chemotherapy. Toxicity was greater for the two- and three-drug combinations than for melphalan. There was no difference in survival following use of the three treatment regimens. Further studies are needed to develop effective chemotherapy for patients with cancer of the pancreas.
在一项针对127例晚期可测量胰腺癌患者的研究中，美法仑的客观缓解率为2%，5-氟尿嘧啶和甲基环己亚硝脲为10%，5-氟尿嘧啶、甲基环己亚硝脲和链脲佐菌素为7%。在28例已接受过先前化疗的接受依托泊苷治疗的患者中未出现缓解情况。两药和三药联合方案的毒性比美法仑更大。三种治疗方案使用后的生存率没有差异。需要进一步开展研究以开发针对胰腺癌患者的有效化疗方法。
